Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1969 1
1975 1
1976 3
1977 2
1978 1
1979 2
1980 1
1981 3
1982 1
1983 4
1984 12
1985 3
1986 3
1987 7
1988 4
1989 11
1990 6
1991 18
1992 7
1993 6
1994 13
1995 16
1996 13
1997 7
1998 12
1999 5
2000 14
2001 16
2002 16
2003 27
2004 16
2005 15
2006 23
2007 19
2008 23
2009 23
2010 30
2011 22
2012 31
2013 37
2014 25
2015 31
2016 31
2017 33
2018 21
2019 28
2020 29
2021 23
2022 28
2023 28
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

689 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Localized Peripheral Primitive Neuroectodermal Tumor"
Page 1
Advancing therapy for neuroblastoma.
Qiu B, Matthay KK. Qiu B, et al. Nat Rev Clin Oncol. 2022 Aug;19(8):515-533. doi: 10.1038/s41571-022-00643-z. Epub 2022 May 25. Nat Rev Clin Oncol. 2022. PMID: 35614230 Review.
Neuroblastomas are tumours of sympathetic origin, with a heterogeneous clinical course ranging from localized or spontaneously regressing to widely metastatic disease. ...Over the past few decades, improvements in the 5-year survival of patients with metastatic neur …
Neuroblastomas are tumours of sympathetic origin, with a heterogeneous clinical course ranging from localized or spontaneously …
Immunotherapy of Neuroblastoma: Facts and Hopes.
Anderson J, Majzner RG, Sondel PM. Anderson J, et al. Clin Cancer Res. 2022 Aug 2;28(15):3196-3206. doi: 10.1158/1078-0432.CCR-21-1356. Clin Cancer Res. 2022. PMID: 35435953 Free PMC article. Review.
Most children with cancer, including high-risk neuroblastoma, do not benefit from treatment with immune checkpoint inhibitors (ICI) that have revolutionized the treatment of many highly immunogenic adult solid tumors. This likely reflects the low tumor mutation burd …
Most children with cancer, including high-risk neuroblastoma, do not benefit from treatment with immune checkpoint inhibitors (ICI) that hav …
Anti-GD2 immunotherapy for neuroblastoma.
Sait S, Modak S. Sait S, et al. Expert Rev Anticancer Ther. 2017 Oct;17(10):889-904. doi: 10.1080/14737140.2017.1364995. Epub 2017 Aug 14. Expert Rev Anticancer Ther. 2017. PMID: 28780888 Free PMC article. Review.
Areas covered: We review the status of anti-GD2 immunotherapies currently in clinical use for neuroblastomas and novel GD2-targeted strategies in preclinical development. ...
Areas covered: We review the status of anti-GD2 immunotherapies currently in clinical use for neuroblastomas and novel GD2-targeted s …
Recent advances in neuroblastoma.
Maris JM. Maris JM. N Engl J Med. 2010 Jun 10;362(23):2202-11. doi: 10.1056/NEJMra0804577. N Engl J Med. 2010. PMID: 20558371 Free PMC article. Review. No abstract available.
Neuroblastoma.
Davidoff AM. Davidoff AM. Semin Pediatr Surg. 2012 Feb;21(1):2-14. doi: 10.1053/j.sempedsurg.2011.10.009. Semin Pediatr Surg. 2012. PMID: 22248965 Free PMC article. Review.
Neuroblastoma is a heterogeneous disease; tumors can spontaneously regress or mature, or display an aggressive, therapy-resistant phenotype. ...Most current clinical studies of neuroblastoma base therapy and its intensity on a risk stratification that takes into acc …
Neuroblastoma is a heterogeneous disease; tumors can spontaneously regress or mature, or display an aggressive, therapy-resistant phe …
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis.
Heczey A, Courtney AN, Montalbano A, Robinson S, Liu K, Li M, Ghatwai N, Dakhova O, Liu B, Raveh-Sadka T, Chauvin-Fleurence CN, Xu X, Ngai H, Di Pierro EJ, Savoldo B, Dotti G, Metelitsa LS. Heczey A, et al. Nat Med. 2020 Nov;26(11):1686-1690. doi: 10.1038/s41591-020-1074-2. Epub 2020 Oct 12. Nat Med. 2020. PMID: 33046868 Clinical Trial.
Valpha24-invariant natural killer T (NKT) cells have shown potent anti-tumor properties in murine tumor models and have been linked to favorable outcomes in patients with cancer. ...Cy/Flu conditioning was the probable cause for grade 3-4 hematologic adverse events, …
Valpha24-invariant natural killer T (NKT) cells have shown potent anti-tumor properties in murine tumor models and have been l …
Children's Oncology Group's 2023 blueprint for research: Bone tumors.
Reed DR, Grohar P, Rubin E, Binitie O, Krailo M, Davis J, DuBois SG, Janeway KA. Reed DR, et al. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30583. doi: 10.1002/pbc.30583. Epub 2023 Jul 27. Pediatr Blood Cancer. 2023. PMID: 37501549
The Children's Oncology Group (COG) Bone Tumor Committee is responsible for clinical trials and biological research on localized, metastatic, and recurrent osteosarcoma and Ewing sarcoma (EWS). ...In addition, the Committee has data analyses and a clinical …
The Children's Oncology Group (COG) Bone Tumor Committee is responsible for clinical trials and biological research on loca …
Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.
Oesterheld J, Ferguson W, Kraveka JM, Bergendahl G, Clinch T, Lorenzi E, Berry D, Wada RK, Isakoff MS, Eslin DE, Brown VI, Roberts W, Zage P, Harrod VL, Mitchell DS, Hanson D, Saulnier Sholler GL. Oesterheld J, et al. J Clin Oncol. 2024 Jan 1;42(1):90-102. doi: 10.1200/JCO.22.02875. Epub 2023 Oct 26. J Clin Oncol. 2024. PMID: 37883734 Free PMC article. Clinical Trial.
Eflornithine (DFMO) to reduce risk of relapse after completion of immunotherapy was investigated previously in a single-arm, phase II study (NMTRC003B; ClinicalTrials.gov identifier: NCT02395666) that suggested improved event-free survival (EFS) and overall survival (OS) compared …
Eflornithine (DFMO) to reduce risk of relapse after completion of immunotherapy was investigated previously in a single-arm, phase II study …
Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial.
Flaadt T, Ladenstein RL, Ebinger M, Lode HN, Arnardóttir HB, Poetschger U, Schwinger W, Meisel R, Schuster FR, Döring M, Ambros PF, Queudeville M, Fuchs J, Warmann SW, Schäfer J, Seitz C, Schlegel P, Brecht IB, Holzer U, Feuchtinger T, Simon T, Schulte JH, Eggert A, Teltschik HM, Illhardt T, Handgretinger R, Lang P. Flaadt T, et al. J Clin Oncol. 2023 Jun 10;41(17):3135-3148. doi: 10.1200/JCO.22.01630. Epub 2023 Feb 28. J Clin Oncol. 2023. PMID: 36854071 Free PMC article. Clinical Trial.
The primary end point 'success of treatment' encompassed patients receiving six cycles, being alive 180 days after end of trial treatment without progressive disease, unacceptable toxicity, acute graft-versus-host-disease (GvHD) grade 3, or extensive chronic GvHD. ...Five- …
The primary end point 'success of treatment' encompassed patients receiving six cycles, being alive 180 days after end of trial treat …
Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531.
Twist CJ, Schmidt ML, Naranjo A, London WB, Tenney SC, Marachelian A, Shimada H, Collins MH, Esiashvili N, Adkins ES, Mattei P, Handler M, Katzenstein H, Attiyeh E, Hogarty MD, Gastier-Foster J, Wagner E, Matthay KK, Park JR, Maris JM, Cohn SL. Twist CJ, et al. J Clin Oncol. 2019 Dec 1;37(34):3243-3255. doi: 10.1200/JCO.19.00919. Epub 2019 Aug 6. J Clin Oncol. 2019. PMID: 31386611 Free PMC article. Clinical Trial.
PATIENTS AND METHODS: Children younger than age 12 years with intermediate-risk stage 2A/2B or stage 3 tumors with favorable histology; infants younger than age 365 days with stage 3, 4 or 4S disease; and toddlers from 365 to younger than 547 days with favorable histology, …
PATIENTS AND METHODS: Children younger than age 12 years with intermediate-risk stage 2A/2B or stage 3 tumors with favorable histolog …
689 results